HCC
BIVV

Hirtle Callaghan & Co’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Hirtle Callaghan & Co’s Portfolio BIVV Stock Details BIVV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-44
Closed -$3K – 223
2017
Q3 		$3K Hold
44
– – ﹤0.01% 195
2017
Q2 		$2K Sell
44
-10
-19% -$569 ﹤0.01% 185
2017
Q1 		$2K Buy
+54
New +$2.66K ﹤0.01% 181

Other funds holding BIVV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Hirtle Callaghan & Co's BIVV Position: Q4 2017 in Review

Hirtle Callaghan & Co sold out of Bioverativ Inc. Common Stock (BIVV) in Q4 2017, closing a stake of 44 shares — an estimated $3K sold.

Hirtle Callaghan & Co first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $3K in Q3 2017. 459 funds tracked by Wall St. Rank hold BIVV as of Q4 2017.

  • Hirtle Callaghan & Co reported no remaining Bioverativ Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Hirtle Callaghan & Co sold 44 Bioverativ Inc. Common Stock shares in Q4 2017, an estimated $3K.
  • Hirtle Callaghan & Co first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
  • Hirtle Callaghan & Co's Bioverativ Inc. Common Stock position peaked at $3K in Q3 2017.
  • 459 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q4 2017.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2017, filed 17 Jan 2018.